-transparent.png){kind=logo}
Since the Human Immunodeficiency Virus Type 1 (HIV-1) was identified as the etiologic agent of the Acquired Immune Deficiency Syndrome (AIDS), the HIV-1 reverse transcriptase (RT) has been the subject of intensive study. The reverse transcription entails the transition of the single-stranded viral RNA into double-stranded proviral DNA, which is then integrated into the host chromosome. Therefore, the HIV-1 reverse transcriptase plays a pivotal role in the life cycle of the virus and is consequently an interesting target for anti-HIV drug therapy. In the first section, we describe the complex process of reverse transcription and the different activities involved in this process. We then highlight the structure-function relationship of the HIV-1 reverse transcriptase, which is of great importance for a better understanding of resistance development, a major problem in anti-AIDS therapies. Finally, we summarize the mechanisms of HIV resistance toward various RT inhibitors and the implications thereof for the current anti-HIV drug therapies.
H Jonckheere, and
J Anné, and
E De Clercq
December 2015,
PLoS pathogens,
H Jonckheere, and
J Anné, and
E De Clercq
January 2002,
Acta poloniae pharmaceutica,
H Jonckheere, and
J Anné, and
E De Clercq
June 2008,
Virus research,
H Jonckheere, and
J Anné, and
E De Clercq
October 2012,
Cold Spring Harbor perspectives in medicine,
H Jonckheere, and
J Anné, and
E De Clercq
January 2014,
Methods in molecular biology (Clifton, N.J.),
H Jonckheere, and
J Anné, and
E De Clercq
June 1994,
Biochemical and biophysical research communications,
H Jonckheere, and
J Anné, and
E De Clercq
November 2006,
PLoS pathogens,
H Jonckheere, and
J Anné, and
E De Clercq
January 2002,
Current pharmaceutical design,
H Jonckheere, and
J Anné, and
E De Clercq
July 1994,
Proceedings of the National Academy of Sciences of the United States of America,
H Jonckheere, and
J Anné, and
E De Clercq
January 2000,
AIDS (London, England),
